A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome - Related Studies

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

This study has been completed.

Study NCT00001123. Last updated on November 11, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Hantavirus Pulmonary Syndrome

2	Additional conditions recognized in this trial
		Syndrome

3	More general conditions related to this trial
		Bunyaviridae Infections
		Disease
		Hantavirus Infections
		Pathologic Processes
		Respiration Disorders
		Respiratory Insufficiency
		Respiratory Tract Diseases
		RNA Virus Infections
		Virus Diseases

4	Interventions listed in this trial
		Ribavirin

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antiviral Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)